Esperion Therapeutics Q4 EPS $(0.50) Misses $(0.48) Estimate, Sales $32.25M Beat $28.70M Estimate
Portfolio Pulse from Benzinga Newsdesk
Esperion Therapeutics (NASDAQ:ESPR) reported Q4 earnings with a loss of $(0.50) per share, missing the $(0.48) estimate, but sales of $32.25M exceeded the $28.70M estimate, marking a 71.38% increase from last year.
February 27, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Esperion Therapeutics reported a Q4 EPS loss of $(0.50), missing estimates, but sales of $32.25M exceeded expectations, showing significant year-over-year growth.
While the EPS miss might concern some investors, the significant sales beat and year-over-year growth could offset negative sentiment. The mixed results present a neutral short-term outlook as the sales growth indicates strong demand for Esperion's products, potentially stabilizing the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100